Galderma Wins FDA Approval For Vectical(TM) Ointment, A Novel Topical Therapy For Mild-to-Moderate Plaque Psoriasis

Podiatry Arena Galderma Wins FDA Approval For Vectical(TM) Ointment, A Novel Topical Therapy For Mild-to-Moderate Plaque Psoriasis

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

Galderma Wins FDA Approval For Vectical(TM) Ointment, A Novel Topical Therapy For Mild-to-Moderate Plaque Psoriasis

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

4th February 2009, 05:30 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 3,062

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 5 Times in 5 Posts

Galderma Wins FDA Approval For Vectical(TM) Ointment, A Novel Topical Therapy For Mild-to-Moderate Plaque Psoriasis

Podiatry Arena members do not see these ads

Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration (FDA) has approved Vectical(TM) (calcitriol) Ointment 3mcg/g, a unique vitamin D3 product for the treatment of mild-to-moderate plaque psoriasis in adults. Psoriasis is a chronic skin disorder that affects 2 to 3 percent of the U.S. population. It is characterized by thick, red, scaly patches of skin and caused by an abnormally high growth rate of skin cells that form thick, dry scales (plaques).

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is Off

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
New Biologic STELARA(TM) Receives Approval In Europe For Treatment Of Moderate To Severe Plaque Psoriasis	RSSFeedBot	Latest Dermatology News	0	23rd January 2009 04:20 AM
New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority For The Treatment Of Moderate To Severe Plaque Psoriasis	RSSFeedBot	Latest Dermatology News	0	28th November 2008 06:20 AM
Synvista Therapeutics Receives Approval To Begin Phase 2 Trial Of Topical SYI-2074 In Psoriasis	RSSFeedBot	Latest Dermatology News	0	30th September 2008 02:40 AM
Voltaren Gel gets FDA approval for topical OA management	NewsBot	General Issues and Discussion Forum	1	23rd October 2007 12:19 PM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 02:57 AM.

User Name		Remember Me?
Password